Blueroot Health Expands Recall of Vital Nutrients Supplements Over Undeclared Allergens

Blueroot Health of Middletown, Connecticut expanded its voluntary recall of Vital Nutrients Aller-C dietary supplements on April 10, widening the scope of a safety alert it first issued two weeks earlier to capture every bottle produced from the same contaminated ingredient batch.

The original alert, announced March 27, covered two specific sub-lots: 25E04-A and 25E04-B. The April 10 expansion now encompasses all product made from lot 25E04, meaning any white plastic bottle of Aller-C containing 100 or 200 capsules with the lot number 25E04, 25E04-A, or 25E04-B and an expiration date of 05/27 printed on the side is affected. Those products were distributed nationwide from September 2025 through March 2026.

The undeclared ingredients are egg, hazelnut, and soy, three of the nine major food allergens recognized under the Food Allergen Labeling and Consumer Protection Act of 2004. None appear on the product label. For people with sensitivities to any of those ingredients, consumption can trigger reactions ranging from hives and swelling to respiratory distress and anaphylaxis, a potentially fatal immune response that requires emergency treatment.

The FDA advises anyone with egg, hazelnut, or soy allergies to stop using the product immediately and to seek medical attention if they have already experienced symptoms. The agency also directs consumers to report adverse events through its MedWatch program. Anyone seeking a refund or replacement can contact Blueroot Health directly at (888) 328-9992, Monday through Friday from 8 a.m. to 7 p.m., or by email at support@vitalnutrients.co.

The recall spotlights a persistent structural vulnerability in the supplement industry. Unlike pharmaceutical drugs, dietary supplements are not subject to premarket approval by the FDA; manufacturers bear the responsibility for verifying that labels accurately reflect contents and that production processes prevent cross-contamination. That regulatory gap helps explain why undeclared allergens continue to surface across the supplement supply chain, often discovered only after internal testing or adverse event reports prompt a second look. Blueroot Health's decision to voluntarily widen the alert after its initial pull suggests the company identified additional at-risk inventory during its investigation of the original lots.

For clinicians treating patients with unexplained allergic episodes, the FDA's notice is a prompt to ask specifically about supplement use. Aller-C is marketed as a supplement that supports immune and respiratory health, meaning patients with seasonal allergies or asthma may be particularly likely to use it and particularly vulnerable to an undetected allergen hidden inside it.